샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795300

세계의 구강암 치료제 시장

Oral Cancer Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

구강암 치료제 세계 시장은 2030년까지 48억 달러에 달할 전망

2024년에 28억 달러로 추정되는 구강암 치료제 세계 시장은 2024-2030년 분석 기간에 CAGR 9.3%로 성장하여 2030년에는 48억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 표적요법은 CAGR 10.5%를 기록하며 분석 기간 종료시에는 36억 달러에 달할 것으로 예측됩니다. 화학요법 분야의 성장률은 분석 기간 CAGR로 6.2%로 추정됩니다.

미국 시장은 7억 6,860만 달러로 추정, 중국은 CAGR 14.6%로 성장 예측

미국의 구강암 치료제 시장은 2024년에 7억 6,860만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 11억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 14.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 4.6%와 8.9%로 예측됩니다. 유럽에서는 독일이 CAGR 약 6.2%로 성장할 것으로 예측됩니다.

세계의 구강암 치료제 시장 - 주요 동향과 촉진요인 정리

구강암 치료의 예후를 개선하는 치료의 발전은?

구강암 치료제는 종양 생물학에 대한 더 깊은 이해와 보다 타겟화된 치료 옵션의 가용성에 힘입어 빠르게 발전하고 있습니다. 수술, 방사선 치료, 화학요법과 같은 표준적인 접근법은 현재 특히 진행성 및 재발성 구강 편평상피암의 경우 표적 치료제 및 면역치료제로 보완되고 있습니다. 이러한 추가 요법은 표적 외 독성을 감소시키고 개인별 맞춤 치료를 가능하게함으로써 생존율과 삶의 질을 개선하는 데 도움을 주고 있습니다.

EGFR 억제제, PD-1/PD-L1 체크포인트 억제제, 혈관신생 억제제는 특정 유전자 프로파일과 면역 마커를 가진 일부 환자군에서 효과를 입증했습니다. 세툭시맙, 니볼루맙, 펨브롤리주맙은 종양의 병기 및 부위에 따라 단독요법 또는 화학방사선요법과의 병용요법으로 치료 프로토콜에 포함되어 있습니다. 이 약제들은 수술 부적응 환자나 기존 치료법에 내성을 보이는 환자에서 더 나은 병세 조절을 가능하게 합니다.

맞춤형 치료와 바이오마커 유도 프로토콜은 어떻게 확산되고 있는가?

종양학 워크플로우에 바이오마커 검사를 통합함으로써 구강암 치료에 대한 보다 맞춤화된 접근이 가능해졌습니다. 종양의 돌연변이, HPV 상태, PD-L1 발현에 대한 분자 프로파일링은 약제 선택과 치료 강도에 대한 정보를 제공하고 있습니다. PD-L1이 고발현된 환자에게는 면역요법이, 증식인자 수용체나 혈관신생인자가 과발현된 환자에게는 분자표적 치료제가 사용되고 있습니다.

구강악성종양에 대한 유전자 치료, 입양 T세포 이식, 암 백신에 대한 조사가 진행 중이며, 일부 초기 임상시험에서는 새로운 면역 조절 경로가 검토되고 있습니다. 또한, 구강점막염 완화, 영양 상태 개선, 통증 관리를 위한 지지요법은 다학제적 치료 접근에 필수적인 요소로 주목받고 있습니다.

치료 접근성은 어디에서 확대되고 있으며, 치료 도입에 영향을 미치는 요인은 무엇인가?

아시아태평양, 라틴아메리카, 중동 일부 지역에서는 환자 수 증가와 의료 인프라 개선으로 인해 구강암 치료제에 대한 접근성이 확대되고 있습니다. 이들 지역에서는 대중의 인식 개선 캠페인, 정부 재정 지원 프로그램, 종양학에 특화된 투자가 적시에 진단과 치료를 시작할 수 있도록 돕고 있습니다.

북미와 유럽에서는 분자진단과 임상시험 참여에 의해 치료가 점점 더 많이 주도되고 있습니다. 학문적 암센터와 통합 치료 시스템은 동반진단 약물과 다학제적 팀에 대한 접근성을 바탕으로 차세대 치료제의 채택을 주도하고 있습니다. 비용, 환자 자격, 방사선 치료 인프라의 가용성은 자원이 부족한 환경에서 치료 선택에 계속 영향을 미치고 있습니다.

구강암 치료제 시장의 성장은 몇 가지 요인에 의해 주도됩니다...

구강암 치료제 시장의 성장은 담배 및 HPV 관련 암 발병률 증가, 면역요법 및 표적 치료제의 발전, 바이오마커 기반 치료 계획으로의 전환 등의 요인에 의해 주도될 것으로 예상됩니다. 전이성 및 재발성 질환 관리에 체크포인트 억제제 및 EGFR 표적 치료제의 사용이 전이성 및 재발성 질환 관리에 대한 임상적 증거에 의해 확대되고 있습니다.

진단 접근성 향상, 병용요법의 출현, 임상시험 활성화로 인해 약물 개발 및 시장 개척이 가속화되고 있습니다. 암 의료 인프라에 대한 투자 증가, 외래 화학요법 및 면역요법 시설에 대한 접근성 확대, 환자들의 인식 개선은 다양한 지역에서 지속적인 시장 확대에 기여하고 있습니다.

부문

제품 유형(표적요법, 화학요법)

조사 대상 기업 사례

  • AstraZeneca plc
  • Bayer AG
  • Bicara Therapeutics Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celtec Biosciences
  • Cellectar Biosciences, Inc.
  • CytomX Therapeutics Inc.
  • Eli Lilly and Company
  • Exelixis Inc.
  • Genentech(Roche Group)
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Innate Pharma
  • Incyte Corporation
  • Kura Oncology Inc.
  • Merck KGaA
  • Merus N.V.
  • NanoBiotix
  • Novartis AG

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.29

Global Oral Cancer Therapeutics Market to Reach US$4.8 Billion by 2030

The global market for Oral Cancer Therapeutics estimated at US$2.8 Billion in the year 2024, is expected to reach US$4.8 Billion by 2030, growing at a CAGR of 9.3% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 10.5% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$768.6 Million While China is Forecast to Grow at 14.6% CAGR

The Oral Cancer Therapeutics market in the U.S. is estimated at US$768.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 14.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Global Oral Cancer Therapeutics Market - Key Trends & Drivers Summarized

What Therapeutic Advancements Are Improving Prognosis in Oral Cancer Treatment?

Oral cancer therapeutics are evolving rapidly, supported by a deeper understanding of tumor biology and the availability of more targeted treatment options. Standard approaches such as surgery, radiation, and chemotherapy are now being supplemented by targeted therapies and immunotherapeutics, particularly in cases of advanced-stage or recurrent oral squamous cell carcinoma. These additions are helping improve survival rates and quality of life by reducing off-target toxicity and enabling personalized care.

EGFR inhibitors, PD-1/PD-L1 checkpoint inhibitors, and angiogenesis blockers have shown effectiveness in subsets of patients with specific genetic profiles or immune markers. Cetuximab, nivolumab, and pembrolizumab are being incorporated into treatment protocols either as monotherapy or in combination with chemoradiation, depending on tumor stage and location. These drugs are enabling better disease control in patients who are ineligible for surgery or resistant to conventional therapies.

How Are Personalized Therapies and Biomarker-Guided Protocols Gaining Traction?

The integration of biomarker testing into oncology workflows is enabling a more tailored approach to oral cancer treatment. Molecular profiling of tumors for mutations, HPV status, and PD-L1 expression is informing drug selection and treatment intensity. Immunotherapy is increasingly being used in patients with high PD-L1 expression, while targeted agents are applied in those with overexpression of growth factor receptors or angiogenic factors.

Research into gene therapy, adoptive T-cell transfer, and cancer vaccines for oral malignancies is ongoing, with several early-stage trials exploring new immunomodulatory pathways. Additionally, supportive therapeutics aimed at reducing oral mucositis, improving nutritional status, and managing pain are gaining attention as essential components of a multidisciplinary treatment approach.

Where Is Therapeutic Access Expanding and What Influences Treatment Adoption?

Access to oral cancer therapeutics is expanding across Asia-Pacific, Latin America, and parts of the Middle East, driven by rising case volumes and improved healthcare infrastructure. Public awareness campaigns, government reimbursement programs, and oncology-focused investments are promoting timely diagnosis and treatment initiation in these regions.

In North America and Europe, treatment is being increasingly guided by molecular diagnostics and clinical trial participation. Academic cancer centers and integrated care systems are leading adoption of next-generation therapeutics, supported by access to companion diagnostics and multidisciplinary teams. Cost, patient eligibility, and availability of radiotherapy infrastructure continue to influence treatment choices in low-resource settings.

Growth in the Oral Cancer Therapeutics market is driven by several factors…

Growth in the oral cancer therapeutics market is driven by factors such as increasing incidence of tobacco- and HPV-related cancers, advancements in immune and targeted therapy, and the shift toward biomarker-guided treatment planning. Adoption of checkpoint inhibitors and EGFR-targeted drugs is expanding as clinical evidence supports their use in managing metastatic and recurrent disease.

Improved access to diagnostics, emergence of combination regimens, and growing clinical trial activity are accelerating drug development and market reach. Rising investments in oncology care infrastructure, expanding access to outpatient chemotherapy and immunotherapy facilities, and increased patient awareness are further contributing to sustained market expansion across diverse geographies.

SCOPE OF STUDY:

The report analyzes the Oral Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Targeted Therapy, Chemotherapy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AstraZeneca plc
  • Bayer AG
  • Bicara Therapeutics Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celtec Biosciences
  • Cellectar Biosciences, Inc.
  • CytomX Therapeutics Inc.
  • Eli Lilly and Company
  • Exelixis Inc.
  • Genentech (Roche Group)
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Immutep Ltd.
  • Innate Pharma
  • Incyte Corporation
  • Kura Oncology Inc.
  • Merck KGaA
  • Merus N.V.
  • NanoBiotix
  • Novartis AG

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oral Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Oral Cancer Globally Spurs Demand for Advanced Therapeutic Options
    • Increasing Adoption of Targeted Therapies Strengthens Business Case for Precision Oncology in Oral Cancer
    • Growth in Immunotherapy Applications Propels Development of Novel Treatment Regimens
    • Advancements in Molecular Diagnostics Drive Demand for Biomarker-Guided Oral Cancer Therapeutics
    • Expanding Pipeline of Small Molecule Inhibitors Enhances Market Prospects for Oral Oncology Drugs
    • Rising Focus on HPV-Associated Oral Cancers Generates Opportunities for Virus-Targeted Therapeutics
    • Integration of Combination Therapy Approaches Throws the Spotlight on Multi-Modal Treatment Strategies
    • Growing Preference for Outpatient and Oral Chemotherapy Supports Market Shift Toward Oral Therapeutics
    • Expansion of Clinical Trials and Global Collaborations Accelerates Drug Development and Market Access
    • Emergence of Personalized Cancer Vaccines Boosts Interest in Immunotherapeutic Solutions
    • Adoption of Companion Diagnostics Strengthens Value Proposition for Precision Oral Cancer Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oral Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oral Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oral Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • JAPAN
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • CHINA
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • EUROPE
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Oral Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Oral Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • FRANCE
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • GERMANY
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Oral Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Oral Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • INDIA
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Oral Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Oral Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Oral Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Oral Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030
  • AFRICA
    • Oral Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Oral Cancer Therapeutics by Product Type - Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Oral Cancer Therapeutics by Product Type - Percentage Breakdown of Value Sales for Targeted Therapy and Chemotherapy for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제